Using an Electronic Tongue to Optimize Taste-Masking in a Lyophilized Orally Disintegrating Tablet Formulation

Under the agreement, the companies will advance development of IBI3009, Innovent’s ADC candidate, which has received IND approvals in the US, China, and Australia.

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

Challenges that can prevent sponsors realizing the full potential of managed access programs can be overcome by embracing a just-in-time manufacturing strategy.

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

Results from a Phase IIb study missed the primary endpoint by failing to achieve statistical significance.

The companies will use Orexo’s powder-based drug delivery technology to develop mucosal vaccines in an inhaled formulation.